Eisai Co., Ltd.: all 644 studies

Page 4 of 7. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic SeizuresCompletedNCT05533814Phase 4
• A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy ParticipantsCompletedNCT05533801Phase 1
• A Study of Lenvatinib in Combination With Pembrolizumab in Korean PatientsCompletedNCT05375136
• A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT05366036
• A Single and Multiple Dose Study of Dotinurad in Chinese Healthy ParticipantsCompletedNCT05278676Phase 1
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus ParticipantsCompletedNCT05278663Phase 1/2
• A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in JapanActive, not recruitingNCT05228158
• A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg)CompletedNCT05225324
• A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) ParticipantsCompletedNCT05225207
• A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal UlcerCompletedNCT05208268
• A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly ParticipantsCompletedNCT05147337Phase 1
• A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)CompletedNCT05137847
• A Study of Subcutaneous Lecanemab in Healthy ParticipantsCompletedNCT05045716Phase 1
• A Study to Evaluate Lemborexant in Milk of Healthy Lactating WomenCompletedNCT04890561Phase 1
• A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult ParticipantsWithdrawnNCT04840927Phase 1
• A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular CarcinomaCompletedNCT04763408
• A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)CompletedNCT04724109
• A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult ParticipantsCompletedNCT04683185Phase 1
• A Study to Assess the Safety and Tolerability of E2730 After Multiple Dose and the Food Effect After Single Dose in Healthy ParticipantsCompletedNCT04676685Phase 1
• A Study to Assess the Safety and Tolerability of E8001 in Healthy Male ParticipantsCompletedNCT04609852Phase 1
• A Study to Evaluate the Safety of DAYVIGO (Lemborexant) Tablets in Participants With Insomnia.CompletedNCT04573556
• A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast CancerCompletedNCT04572295Phase 1
• Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerCompletedNCT04568902Phase 1
• A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy ParticipantsCompletedNCT04565574Phase 1
• A Single and Multiple Dose Study of Lemborexant in Healthy Chinese ParticipantsCompletedNCT04555733Phase 1
• A Study to Assess the Safety and Tolerability of E2511 in Healthy ParticipantsCompletedNCT04547361Phase 1
• A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male ParticipantsCompletedNCT04493255Phase 1
• AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate AmyloidActive, not recruitingNCT04468659Phase 3
• Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory EpilepsiesNo longer availableNCT04457687
• A Study to Determine the Signs and Symptoms That Impact Daily Life of Participants With Irregular Sleep-Wake Rhythm DisorderCompletedNCT04300569
• A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCCCompletedNCT04297254Phase 4
• A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal SeizuresCompletedNCT04257604
• A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized EpilepsyCompletedNCT04252846
• A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene FusionCompletedNCT04238715Phase 2
• A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy ParticipantsCompletedNCT04231513Phase 1
• A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With EpilepsyCompletedNCT04230044
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability, and Food-effects of EA1080 in Healthy Caucasian and Japanese Male ParticipantsCompletedNCT04223960Phase 1
• A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic SeizuresCompletedNCT04202159
• A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102WithdrawnNCT04109092Phase 1
• A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid TumorActive, not recruitingNCT04078295Phase 1/2
• A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male ParticipantsCompletedNCT04023877Phase 1
• A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood EpilepsyActive, not recruitingNCT04015141Phase 2
• A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorActive, not recruitingNCT04008797Phase 1/2
• A Study of Overall Survival in Participants With Unresectable Hepatocellular CarcinomaCompletedNCT04008082
• A Food-Effect Study of E7386 in Healthy ParticipantsCompletedNCT03996226Phase 1
• A Single Intravenous Dose of E3112 in Japanese Healthy Adult Male ParticipantsCompletedNCT03922633Phase 1
• A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseaseActive, not recruitingNCT03887455Phase 3
• A Pharmacokinetic (PK) Study of Three Types of E0302 Sustained Release (SR) Tablets Compared With E0302 Immediate Release (IR) Tablet Under Fed Conditions in Healthy ParticipantsCompletedNCT03885882Phase 1
• A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or OlderCompletedNCT03836924
• A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)Active, not recruitingNCT03833700Phase 1
• Safety and Pharmacokinetics Study of E2007 to Treat Partial and Generalised Seizures in People With EpilepsyCompletedNCT03780907Phase 2
• A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular CarcinomaCompletedNCT03663114
• A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy ParticipantsCompletedNCT03627936Phase 1
• A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast CancerCompletedNCT03583944Phase 4
• A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid CancerCompletedNCT03573960Phase 4
• Clinical Trial of Ultra-high Dose Methylcobalamin for ALSCompletedNCT03548311Phase 3
• Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in BrazilApproved for marketingNCT03533361
• A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative ColitisCompletedNCT03531892Phase 3
• Study of Lemborexant-Alcohol Interaction in Healthy SubjectsCompletedNCT03483636Phase 1
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730 in Healthy ParticipantsCompletedNCT03451890Phase 1
• Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy SubjectsCompletedNCT03451110Phase 1
• A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World SettingCompletedNCT03448445
• A Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male ParticipantsCompletedNCT03444818Phase 1
• A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer ParticipantsCompletedNCT03437083
• A Study to Evaluate the Food-Effect of H3B-6527CompletedNCT03424577Phase 1
• Pharmacokinetic Study of Perampanel in Chinese Healthy SubjectsCompletedNCT03424564Phase 1
• Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male SubjectsTerminatedNCT03402178Phase 1
• Bioequivalence Study Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese SubjectsCompletedNCT03399734Phase 1
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Adult Male ParticipantsWithdrawnNCT03390647Phase 1
• A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid TumorsCompletedNCT03386942Phase 1
• Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy SubjectsCompletedNCT03376997Phase 1
• Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real WorldCompletedNCT03264703
• Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD PatientsCompletedNCT03264690
• Study of E7386 in Participants With Selected Advanced NeoplasmsActive, not recruitingNCT03264664Phase 1
• Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With EpilepsyCompletedNCT03208660
• Study of E7389 Liposomal Formulation in Participants With Solid TumorActive, not recruitingNCT03207672Phase 1
• A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative UsersCompletedNCT03158025Phase 1
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed StateCompletedNCT03133468Phase 1
• Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic AcidTerminatedNCT03092765Phase 2
• Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult SubjectsCompletedNCT03082235Phase 1
• ZEDEBAC: Zebinix Effects in Dependency of Baseline ConditionsCompletedNCT03082222
• Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic SeizuresCompletedNCT03059381
• Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic SeizuresCompletedNCT03059329
• A Study on Safety and Efficacy in Patients With Soft Tissue SarcomasCompletedNCT03058406
• Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese SubjectsCompletedNCT03055962Phase 1
• Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730CompletedNCT03054194Phase 1
• Incidence and Resolution of Eribulin-Induced Peripheral NeuropathyCompletedNCT03027245
• Study of E6007 in Japanese Patients With Moderate Active Ulcerative ColitisCompletedNCT03018054Phase 2
• A Single Intravenous Dose Study of E3112 in Japanese Healthy Adult Male SubjectsCompletedNCT03014895Early Phase 1
• Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid TumorCompletedNCT03009292Phase 1
• Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and OlderCompletedNCT03008447Phase 1
• To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid TumorsCompletedNCT03002493Phase 1
• Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein BindingCompletedNCT02998775Early Phase 1
• A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in ChinaCompletedNCT02966093Phase 3
• General Clinical Study of AJG555 in Pediatric Patients With Chronic ConstipationCompletedNCT02961556Phase 3
• Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT02953743Phase 1
• Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy SubjectsCompletedNCT02947711Phase 1
• A Single Dose Study of E6130 in Japanese Healthy Adult Male SubjectsCompletedNCT02902978Phase 1
• A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy SubjectsCompletedNCT02873156Phase 1
• A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy SubjectsCompletedNCT02859207Phase 1

← Eisai Co., Ltd. overview and focus areas